NETHERLANDS - Institutional investors could increase their weightings in pharmaceutical firms if the industry examines a new study, according to Martin Eijgenhuijsen senior portfolio manager at ABP Investments.
Eijgenhuijsen reportedly made the comments after the conclusions of the Pharma Futures report were published yesterday. The study urged the industry to shift to more targeted portfolios and to ...
To continue reading this article...
Join Professional Pensions
- Unlimited access to real-time news, analysis and opinion from the industry
- Receive our in-depth monthly magazine in either print or digital format
- Access our Sustainable Investment Hub covering news and opinion from thought leaders in the ESG space
- Receive important and breaking news stories selected by the Editors in our daily newsletter
- Hear from industry experts and other forward-thinking leaders
- Receive a monthly members-only newsletter with exclusive opinion pieces from leading industry experts and a feature from the magazine in advance of its release date